Edward L. Erickson has been named president and chiefexecutive officer of Cholestech Corp. of Hayward, Calif. Ericksonwas president of Serono-Baker Diagnostics Inc., a subsidiary ofthe Ares-Serono Group. Privately held Cholestech specializes inproducts for the diagnosis, monitoring and treatment of lipiddisorders.
Privately held United Biomedical Inc. of Lake Success, N.Y., hasappointed Z. Jerry Kuliga president and CEO. Kuliga co-foundedMicroScan, a division of Baxter Healthcare Corp. UnitedBiomedical is focused on developing diagnostics and vaccinesfor AIDS, hepatitis C, HTLV and other infectious diseases.
CoCensys Inc., a privately held company focused on theidentification of novel receptors and their complementaryinteracting ligands, has appointed Daniel L. Korpolinskipresident and CEO. Korpolinski, who was president of AdriaLaboratories, North America, replaces Robert G. McNeil, whowill become chairman. The Irvine, Calif., company alsopromoted Kelvin W. Gee, Ph.D., to chief scientific officer andappointed Donald W. Ashbrook, Ph.D., vice president ofscientific affairs.
Biogen Inc. (NASDAQ:BGEN) of Cambridge, Mass., has appointedLawrence S. Daniels vice president of marketing and businessdevelopment. Daniels had been vice president of corporatestrategy development at Allied Signal Inc.
Dr. Samuel R. Saks has been appointed vice president of clinicalresearch, oncology, for Schering-Plough Research of Kenilworth,N.J. Saks was vice president of clinical research at Xoma Corp.
Dr. Michael Sabolinski has joined Marrow-Tech Inc. of La Jolla,Calif., as vice president of clinical research. Sabolinski wasdirector of medical operations for Sandoz Pharmaceutical Corp.Marrow-Tech (NASDAQ:MAROA) is engaged in the growth ofhuman tissue outside the body.
Calgene Inc. of Davis, Calif., promoted Vic Knauf to vicepresident for research. He had been oilseeds division researchdirector. Calgene (NASDAQ:CGNE) focuses on plantbiotechnology.
Horst Witzel, a member of the advisory board of Schering AG,and Richard D. Johnson, former corporate vice president ofMarion Merrell Dow, have been appointed to the board atImmunoPharmaceutics Inc. The San Diego affiliate of SynbioticsCorp. focuses on rational drug design.
VimRx Pharmaceuticals Inc. of Stamford, Conn., has elected toits board William I. Bergman, president of The Council OnFamily Health and recently retired president of Richardson-Vicks USA. VimRx (NASDAQ:VMRX) is engaged in the researchand development of therapies for blood-borne viral andretroviral diseases.
(c) 1997 American Health Consultants. All rights reserved.